Utility of single nucleotide polymorphism status of vascular endothelial growth factor in predicting long-term effects of bevacizumab in treating metastatic colorectal cancer

The aim of the current study was to investigate the relationship between Single Nucleotide Polymorphisms (SNPs) of Vascular Endothelial Growth Factor (VEGF) in peripheral blood vessels and the prognosis of patients with Metastatic Colorectal Cancer (MCC). Peripheral blood samples of a total of 60 MCC patients treated in our hospital from 2012 to 2015 were tested for nine VEGF SNPs by MassARRAY, including -2578Cu003eA, -460Tu003eC, -1455Tu003eC, -1154Gu003eA, -634Gu003eC, -398Gu003eA, -497Tu003eC, -2455u003e-T, and -936Cu003eT. For the 60 MCC patients, the SNP variability for VEGF was similar to that in the NCBI database; the Overall Survival (OS) of patients homozygous for SNP-497TT was worse than that of patients with other SNPs (P=0.02). Among the patients treated with Bevacizumab (BEV), the OS for three SNP-497 genotypes showed significance (P=0.01), the OS of patients homozygous for SNP-398AA and SNP-2455CC was better than that of patients with the other SNPs (P=0.02, and P=0.01, respectively). The SNP status of VEGF in peripheral blood may be related to BEV treatment and longterm chemotherapeutic efficacies.